Neuroendocrine neoplasms (NENs) are a heterogeneous group of tumors originating from the diffuse neuroendocrine cells found throughout the body, albeit they most frequently arise from the digestive system. NENs include well-differentiated neuroendocrine tumors (NETs), which represent the majority of cases, and poorly differentiated neuroendocrine carcinomas (NECs). Most NENs are sporadic, although they might arise in the setting of genetic syndromes, such as the multiple endocrine neoplasia type 1 (MEN1) syndrome. Thanks to advances in radiological, nuclear medicine, and anatomopathological diagnostics, the incidence of NENs is has increased more than six-fold in the last decades, reaching an incidence of 7/100,000 cases. Moreover, thanks to the multi-disciplinarity approach and to the integrated role of endocrinological and oncological research, NENs probably represent the subgroup of neoplasms that recorded the most sensitive progress in medical treatments.
The NIKE (Neuroendocrine Tumors, Innovation in Knowledge and Education) project is a good opportunity to interact with the major experts in the field of NENs coming from different specialist branches. The annual conference analyzes the hot-topics that have emerged in the last years in the field of NENs, with particular attention to molecular biology, tumor classification, diagnosis and prognosis, and therapeutic novelties. In addition, every years' multidisciplinary study-groups are organized with the aim of analyzing the current controversial topics on NENs. The final aim is to raise up and publish review articles, even supported by a retrospective collection of data, if available.
The discussion raised up by the NIKE conference has the aim to support a common and multidisciplinary approach for the diagnosis and treatment of patients affected by NENs.
Details for Authors
Review articles and original papers focusing on epidemiology, pathogenesis, diagnosis, natural history, prognosis, and treatment of neuroendocrine tumors are welcome.
Hot topics include, but are not limited to:
1. Neuroendocrine neoplasms (NENs) of the gastro-entero-pancreatic tract (GEP-NENs), lung and bronchial NENs, NEN of the thymus, NEN of the genitourinary tract.
2. Medullary thyroid carcinoma.
3. Pheochromocytoma and paraganglioma.
4. Merkel cell carcinoma.
5. Other types of rare neuroendocrine tumors.
6. Multiple endocrine neoplasia type 1 (MEN1), and type 2 (MEN2), Neurofibromatosis type 1, von Hippel-Lindau.
7. Molecular markers of prognosis and/or diagnosis, including micro-RNA.
8. Efficacy and prognostic factors of treatment with somatostatin analogs, targeted therapies, Peptide Receptor Radionuclide Therapy (PRRT), standard chemotherapies, and new proposed therapies.
9. Quality of life and comorbidities in patients with NENs.
10. A multidisciplinary approach to patients with NENs.
Neuroendocrine neoplasms (NENs) are a heterogeneous group of tumors originating from the diffuse neuroendocrine cells found throughout the body, albeit they most frequently arise from the digestive system. NENs include well-differentiated neuroendocrine tumors (NETs), which represent the majority of cases, and poorly differentiated neuroendocrine carcinomas (NECs). Most NENs are sporadic, although they might arise in the setting of genetic syndromes, such as the multiple endocrine neoplasia type 1 (MEN1) syndrome. Thanks to advances in radiological, nuclear medicine, and anatomopathological diagnostics, the incidence of NENs is has increased more than six-fold in the last decades, reaching an incidence of 7/100,000 cases. Moreover, thanks to the multi-disciplinarity approach and to the integrated role of endocrinological and oncological research, NENs probably represent the subgroup of neoplasms that recorded the most sensitive progress in medical treatments.
The NIKE (Neuroendocrine Tumors, Innovation in Knowledge and Education) project is a good opportunity to interact with the major experts in the field of NENs coming from different specialist branches. The annual conference analyzes the hot-topics that have emerged in the last years in the field of NENs, with particular attention to molecular biology, tumor classification, diagnosis and prognosis, and therapeutic novelties. In addition, every years' multidisciplinary study-groups are organized with the aim of analyzing the current controversial topics on NENs. The final aim is to raise up and publish review articles, even supported by a retrospective collection of data, if available.
The discussion raised up by the NIKE conference has the aim to support a common and multidisciplinary approach for the diagnosis and treatment of patients affected by NENs.
Details for Authors
Review articles and original papers focusing on epidemiology, pathogenesis, diagnosis, natural history, prognosis, and treatment of neuroendocrine tumors are welcome.
Hot topics include, but are not limited to:
1. Neuroendocrine neoplasms (NENs) of the gastro-entero-pancreatic tract (GEP-NENs), lung and bronchial NENs, NEN of the thymus, NEN of the genitourinary tract.
2. Medullary thyroid carcinoma.
3. Pheochromocytoma and paraganglioma.
4. Merkel cell carcinoma.
5. Other types of rare neuroendocrine tumors.
6. Multiple endocrine neoplasia type 1 (MEN1), and type 2 (MEN2), Neurofibromatosis type 1, von Hippel-Lindau.
7. Molecular markers of prognosis and/or diagnosis, including micro-RNA.
8. Efficacy and prognostic factors of treatment with somatostatin analogs, targeted therapies, Peptide Receptor Radionuclide Therapy (PRRT), standard chemotherapies, and new proposed therapies.
9. Quality of life and comorbidities in patients with NENs.
10. A multidisciplinary approach to patients with NENs.
